EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial

Ana M Solares, Idania Baladron, Thelvia Ramos, Carmen Valenzuela, Zaida Borbon, Sonia Fanjull, Leonardo Gonzalez, Dagnelia Castillo, Julio Esmir, Milaid Granadillo, Aileen Batte, Alberto Cintado und 5 weitere

ISRN Obstetrics and Gynecology · 2011

DOI: 10.5402/2011/292951 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ISRN Obstetrics and Gynecology, 2011. Verfasst von Ana M Solares und 16 weiteren Autor:innen. Beteiligte Einrichtung: Gyneco-obstetric Hospital Ramon Gonzalez Coro, Havana 10400, Cuba. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

CIGB-228 is a novel therapeutic vaccine consisting of HLA-restricted HPV16 E7 epitope adjuvated with VSSP. This trial was designed to evaluate the toxicity, safety, immunogenicity, HPV clearance, and lesion regression.

Methods

Seven women were entered. All were HLA-A2 positive, had biopsy-proven high-grade CIN, histologically positive for HPV16, and beared persistent postbiopsy lesions visible by digital colposcopy. HLA-A2 women with biopsy-proven high-grade CIN, HPV16-positive, and beared persistent postbiopsy lesions visible by digital colposcopy were vaccinated. One weekly injections of CIGB-228 vaccine was given for four weeks. Then, loop electrosurgical excision procedure (LEEP) of the transformation zone was performed. Study subjects were followed for 1 year after LEEP.

Results

No toxicity beyond grade 1 was observed during and after the four vaccinations. Five of seven women had complete and partial regression. Cellular immune response was seen in all patients. HPV was cleared in three of the patients with complete response.

Conclusion

CIGB-228 vaccination was well tolerated and capable to induce IFN-associated T-cell response in women with high-grade CIN. In several patients, lesion regression and HPV clearance were observed.

Autor:innen und Institutionen

  • Gyneco-obstetric Hospital Ramon Gonzalez Coro, Havana 10400, Cuba.

Zitieren

APA

Solares, A. M., Baladron, I., Ramos, T., Valenzuela, C., Borbon, Z., Fanjull, S., Gonzalez, L., Castillo, D., Esmir, J., Granadillo, M., Batte, A., Cintado, A., Ale, M., Fernandez de Cossio, M. E., Ferrer, A., Torrens, I., & Lopez-Saura, P. (2011). Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial. ISRN Obstetrics and Gynecology. https://doi.org/10.5402/2011/292951

Vancouver

Solares AM, Baladron I, Ramos T, Valenzuela C, Borbon Z, Fanjull S, et al. Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial. ISRN Obstetrics and Gynecology. 2011. doi:10.5402/2011/292951

BibTeX
@article{Solares2011,
  author = {Solares, Ana M and Baladron, Idania and Ramos, Thelvia and Valenzuela, Carmen and Borbon, Zaida and Fanjull, Sonia and Gonzalez, Leonardo and Castillo, Dagnelia and Esmir, Julio and Granadillo, Milaid and Batte, Aileen and Cintado, Alberto and Ale, Mayte and Fernandez de Cossio, Maria E and Ferrer, Annia and Torrens, Isis and Lopez-Saura, Pedro},
  title = {Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial},
  journal = {ISRN Obstetrics and Gynecology},
  year = {2011},
  doi = {10.5402/2011/292951}
}
Kostenlos starten →